drugset / Trial / NCT05607095
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
Phase 1
Recruiting
40 enrolled
Memorial Sloan Kettering Cancer Center
Iovance Biotherapeutics, Inc. · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is an open label study evaluating lifileucel (LN-144) in patients with metastatic uveal melanoma.
Timeline
- Start
- 2022-11-01
- Primary completion
- 2027-05-01
- Completion
- 2027-05-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tumor Infiltrating Lymphocytes | Cell therapy | — | — |